Antimicrobial Resistance (AMR) and the financial sector

Question Title

* 1. I agree that the information provided can be aggregated and used anonymously.

Yes

No

Question Title

* 2. Is there an exposure to the following sectors? (Multiple answers possible)

Big Food

Livestock production

Pharmaceutical industry

Question Title

* 3. Does the investor consider the link between public health and animal welfare in its RI strategy, policy and instruments?

No, neither public health nor animal welfare are focus topics for the investor.

No, but either public health or animal welfare is addressed in the investor’s RI policy and/or RI instruments.

Yes, public health and animal welfare are addressed in tandem in the RI policy and/or RI instruments.

Question Title

* 4. Is AMR considered to be a significant issue with regards to sustainability and/or business risks?

Yes.

No.

Question Title

* 5. To what extent does the investor expect to have to deal with the business risks associated with AMR?

Risks are considered to be low to insignificant, no or little action necessary.

Risks are considered to be moderate, requiring some further action.

Risks are considered to be significant, requiring extensive further action.

Question Title

* 6. What would help the investor integrate AMR, animal welfare and public health into its RI activities? (For example, knowledge sharing, collective engagement etc.).

Question Title

* 7. Does the investor have any further remarks on the topics of AMR, animal welfare and/or public health?

Question Title

* 8. Optional: leave your contact information below if you'd like to be informed about further activities on AMR by VBDO.